Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down

July 9, 2026 10:00 AM EDT DealsPharma Lil­ly was al­ready phar­ma's biggest com­pa­ny. Now it's do­ing deals to match Kyle LaHucik Biotech Correspondent Rid­ing on its tril­lion-dol­lar heft and suc­cess­es in treat­ing obe­si­ty, Eli Lil­ly has now be­come a force in one area where it … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER